Zum Inhalt

HealthOSArzneimittel

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (1)

Nebenwirkungen · Tyverb

Tyverb 250 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9–10

HOS-208948 · Präparat HOS-154213

9 Immune system disorders Rare Hypersensitivity reactions including anaphylaxis (see section 4.3) Metabolism and nutrition disorders Very common Anorexia Psychiatric disorders Very common Insomnia* Nervous system disorders Very common Headache† Common Headache* Cardiac disorders Common Decreased left ventricular ejection fraction (see section 4.2 - dose reduction – cardiac events and section 4.4). Not known Ventricular arrhythmias/Torsades de Pointes, electrocardiogram QT prolonged** Vascular disorders Very common Hot flush† Respiratory, thoracic and mediastinal disorders Very common Epistaxis†, cough†, dyspnoea†. Uncommon Interstitial lung disease/pneumonitis. Not known Pulmonary arterial hypertension**. Gastrointestinal disorders Very common Diarrhoea, which may lead to dehydration (see section 4.2 - dose delay and dose reduction – other toxicities and section 4.4), nausea, vomiting, dyspepsia*, stomatitis*, constipation*, abdominal pain*. Common Constipation† Hepatobiliary disorders Common Hyperbilirubinaemia, hepatotoxicity (see section 4.4). Skin and subcutaneous tissue disorders Very common Rash (including dermatitis acneiform) (see section 4.2 - dose delay and dose reduction – other toxicities), dry skin*†, palmar-plantar erythrodysaesthesia*, alopecia†, pruritus†. Common Nail disorders including paronychia, skin fissures. Not known Serious cutaneous reactions, including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)** Musculoskeletal and connective tissue disorders Very common Pain in extremity*†, back pain*†, arthralgia†. General disorders and administration site conditions Very common Fatigue, mucosal inflammation*, asthenia†. * These adverse reactions were observed when lapatinib was administered in combination with capecitabine. † These adverse reactions were observed when lapatinib was administered in combination with letrozole. ** Adverse reactions from spontaneous reports and literature

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-01-06T15:40:00Z · SHA-256 cc5bd96641c0b3f4003ec76839196782d898a5b2fc432b1735c84b65f7171b92 · Passage 8ccf83e85c65d9b6b8c816db06b6edaee36ba2ba1e09bdfb221fd9fe51f36e7b · Zeichen 2033–4444 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.